Europeans Give Positive Opinion for Velcade Against Mantle Cell Lymphoma

The Committee for Medicinal Products for Human Use of the European Medicines Agency has given a positive opinion on the use of Bortezomib (Velcade) in mantle cell lymphoma (MCL).

Previously, Velcade was only approved by the regulatory agency for the treatment of multiple myeloma.

This new indication covers the use of bortezomib, in combination with rituximab, cyclophosphamide, doxorubicin, and prednisone (R-CAP), for the treatment of adult patients with previously untreated MCL who are unsuitable for hematopoietic stem cell transplantation.

Velcade was recently approved by the US FDA for the same indication.

The agency's positive opinion is based on data from the phase 3 study, LYM-3002, conducted in 487 patients with newly diagnosed MCL who were ineligible for bone marrow transplant, which was presented at the 2014 American Society of Clinical Oncology annual meeting (J Clin Oncol. 2014;32[15 Suppl]:8500).

Patients were randomized to receive one of two drug combinations: either the widely used standard of care combination containing rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP); or the new combination containing bortezomib, rituximab, cyclophosphamide, doxorubicin (Adriamycin), and prednisone (VR-CAP).

The results show that the VR-CAP regimen significantly improved progression-free survival, among other end points.

An independent review committee reported the increase in progression-free survival to be 59% (median, 24.7 vs 14.4 months; hazard ratio [HR], 0.63; P

Bortezomib was associated with additional, but manageable, toxicity when compared with the standard regimen, the manufacturer notes.

SourceL Medscape

More Articles

More Articles

There are two types of cancer: benign and malignant. Benign cancers are the kind that don't spread and don't threaten one's life. Malignant...

Hodgkin's Disease—also referred to as Hodgkin's Lymphoma, these are the exact same diseases, just...

The Follicular Lymphoma International Prognostic Index, or FLIPI, is a standardized guide to help oncological diagnosticians accurately calculate...

Diffuse large B cell lymphoma prognosis is contingent upon several factors, and can be determined by using a well-...

The term 'metastatic lymphoma' does not refer to a diagnosis. Unlike many of the subtypes of lymphoma we have...

Diagnosing lymphoma is one of the more difficult diagnoses to make in cancer medicine, and contrary to perception, diagnosing lymphoma is not made...

Burkitt's lymphoma is an aggressive B-cell lymphoma that is common in children...

Treatment for Non-Hodgkin’s Lymphomas (NHL) differs from patient to patient. The regimen used depends on the type of...

Large Cell Lymphoma (LCL) is typically an aggressive (fast growing) cancer of either the B cell or T cell type. They are one of the most common...

Follicular lymphoma is classified as a Non-Hodgkin's Lymphoma. It is an indolent (slow-growing) cancer that affects...

Aggressive Non-Hodgkin’s Lymphomas (NHLs) are fast growing cancers (as opposed to indolent cancers). They involve...

Lymphoma is not difficult to diagnose once a patient and doctor begin to look for signs of cancer. However, Lymphoma–especially...

A lymphoma prognosis varies greatly depending on the type of lymphoma. There are more than 35 types of lymphoma, including 5 types of...

The lymphatic system, or lymph system, defends the body from foreign invasion by disease causing agents such as viruses, bacteria, or fungi. The...

Lymphoma is a cancer of the lymphatic system, causing B-cell or...